Overview

  • Product name

    Anti-IDI1 + IDI2 antibody [EPR17213]
    See all IDI1+IDI2 primary antibodies
  • Description

    Rabbit monoclonal [EPR17213] to IDI1 + IDI2
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WBmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    within Human IDI1 aa 150 to the C-terminus. The exact sequence is proprietary.
    Database link: Q13907

  • Positive control

    • WB: HepG2, HeLa and MOLT-4 whole cell lysates; Human fetal liver, fetal kidney, fetal skeletal muscle lysate, colon cancer lysates.
  • General notes

     

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab205617 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 26 kDa (predicted molecular weight: 26 kDa).

Target

Images

  • All lanes : Anti-IDI1 + IDI2 antibody [EPR17213] (ab205617) at 1/5000 dilution

    Lane 1 : HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate
    Lane 2 : HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate with IDI1 peptide
    Lane 3 : HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate with IDI2 peptide

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

    Developed using the ECL technique.

    Predicted band size: 26 kDa
    Observed band size: 26 kDa


    Exposure time: 3 minutes


    Blocking and diluting buffer was 5% NFDM /TBST.

  • Anti-IDI1 + IDI2 antibody [EPR17213] (ab205617) at 1/5000 dilution + Human fetal liver lysate at 10 µg

    Secondary
    Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/10000 dilution

    Developed using the ECL technique.

    Predicted band size: 26 kDa
    Observed band size: 26 kDa


    Exposure time: 3 minutes


    Blocking and diluting buffer was 5% NFDM /TBST.

  • All lanes : Anti-IDI1 + IDI2 antibody [EPR17213] (ab205617) at 1/1000 dilution

    Lane 1 : Human fetal kidney lysate
    Lane 2 : Human fetal skeletal muscle lysate
    Lane 3 : Human colon cancer lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/10000 dilution

    Developed using the ECL technique.

    Predicted band size: 26 kDa
    Observed band size: 26 kDa


    Exposure time: 3 minutes


    Blocking and diluting buffer was 5% NFDM /TBST

  • All lanes : Anti-IDI1 + IDI2 antibody [EPR17213] (ab205617) at 1/5000 dilution

    Lane 1 : HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate
    Lane 2 : HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate
    Lane 3 : MOLT-4 (Human lymphoblastic leukemia cell line) whole cell lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

    Developed using the ECL technique.

    Predicted band size: 26 kDa
    Observed band size: 26 kDa


    Exposure time: 2 minutes


    Blocking and diluting buffer was 5% NFDM /TBST

    Exposure time Lane 1 and 2: 2minutes;
    Lane 3: 3minutes

References

ab205617 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab205617.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up